<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t3" orientation="portrait" position="float">
 <label>TABLE III</label>
 <caption>
  <title>Clinical studies of drug repurposing for coronavirus disease 2019 (COVID-19)</title>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
  </colgroup>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Repurposed drug</td>
    <td align="center" rowspan="1" colspan="1">Study characteristics</td>
    <td align="center" rowspan="1" colspan="1">Estimated enrolment</td>
    <td align="center" rowspan="1" colspan="1">Dosage</td>
    <td align="center" rowspan="1" colspan="1">Characteristics of the study and conclusion</td>
    <td align="center" rowspan="1" colspan="1">Clinical trial and recruitment status</td>
   </tr>
   <tr>
    <td align="left" rowspan="3" colspan="1">Remdesivir (8)</td>
    <td align="center" rowspan="3" colspan="1">Phase III, double-blind, randomised, placebo-controlled, multicentre</td>
    <td align="center" rowspan="1" colspan="1">308 patients</td>
    <td align="center" rowspan="3" colspan="1">200 mg Intravenously on the first day plus 100 mg once daily, for more nine consecutive days</td>
    <td align="center" rowspan="1" colspan="1">Adult patients with mild and moderate COVID-19, no published results</td>
    <td align="center" rowspan="1" colspan="1">NCT04252664 (suspended by epidemic control in China with no eligible patients)</td>
   </tr>
   <tr>
    <td align="center" rowspan="1" colspan="1">237 patients</td>
    <td align="center" rowspan="1" colspan="1">Adult patients with severe COVID-19, remdesivir (8) was not associated with clinical benefits in severe forms. However, an observed numerical reduction in time to clinical improvement in patients treated earlier, but still requires confirmation</td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B215" ref-type="bibr">
      <sup>215</sup>
     </xref>; NCT04257656 (terminated by epidemic control in China with no eligible patients)
    </td>
   </tr>
   <tr>
    <td align="center" rowspan="1" colspan="1">1063 patients</td>
    <td align="center" rowspan="1" colspan="1">Remdesivir (8) treated patients with lower respiratory tract infection have a shorter time to recovery compared to placebo group (11 vs 15 days)</td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B216" ref-type="bibr">
      <sup>216</sup>
     </xref>; NCT04280705
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Chloroquine (20)</td>
    <td align="center" rowspan="1" colspan="1">Multicentre</td>
    <td align="center" rowspan="1" colspan="1">&gt; 100 patients</td>
    <td align="center" rowspan="1" colspan="1">500 mg per day, for 10 days</td>
    <td align="center" rowspan="1" colspan="1">Compilation of various clinical studies that are in course, authors conclude that the dosage used could be sufficient</td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B217" ref-type="bibr">
      <sup>217</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="center" rowspan="1" colspan="1">Phase IIb Double-blind, randomised</td>
    <td align="center" rowspan="1" colspan="1">81 patients</td>
    <td align="center" rowspan="1" colspan="1">600 mg twice daily for 10 days and 450 mg twice on the first day, once daily for more 4 days</td>
    <td align="center" rowspan="1" colspan="1">Higher dosage of chloroquine (20) has toxic effects and increased lethality, with any clinical benefit</td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B218" ref-type="bibr">
      <sup>218</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Hydroxychloroquine (26)</td>
    <td align="center" rowspan="1" colspan="1">non-randomised, non-double-blind, non-placebo-controlled</td>
    <td align="center" rowspan="1" colspan="1">36 patients</td>
    <td align="center" rowspan="1" colspan="1">600 mg of hydroxychloroquine (26) daily for 10 days</td>
    <td align="center" rowspan="1" colspan="1">Hydroxychloroquine (26) significantly reduces viral load despite small sample size</td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B219" ref-type="bibr">
      <sup>219</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Ritonavir (2)/lopinavir (1)</td>
    <td align="center" rowspan="1" colspan="1">Randomised, controlled, open-label</td>
    <td align="center" rowspan="1" colspan="1">199 patients</td>
    <td align="center" rowspan="1" colspan="1">400 mg/100 mg twice a day for 14 days</td>
    <td align="center" rowspan="1" colspan="1">No benefit was observed with lopinavir (1)-ritonavir (2) treatment compared to standard care in severe Covid-19 patients</td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B220" ref-type="bibr">
      <sup>220</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Ritonavir (2)/lopinavir (1) plus interferon</td>
    <td align="center" rowspan="1" colspan="1">Phase II, randomised, controlled, open-label</td>
    <td align="center" rowspan="1" colspan="1">127 participants</td>
    <td align="center" rowspan="1" colspan="1">400 mg/100 mg twice a day for 14 days; Interferon Beta-1B plus 0.25 mg subcutaneous injection alternate day for three days</td>
    <td align="center" rowspan="1" colspan="1">Completed with no published results until this moment</td>
    <td align="center" rowspan="1" colspan="1">NCT04276688</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
